Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Population-based assessment of SARS-CoV-2 infection among people living with HIV and the general population of Catalonia (March–December, 2020)

Daniel K. Nomah a,b,c, Yesika Díaz a,c, Rosa M. Vivanco-Hidalgo d, Jordi Casabona a,b,c,e, Jose M. Miro f,g,1, Juliana Reyes-Urueña a,c,e,1, the COVID-19-PISCIS research group

a Centre Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT), Dept Salut, Generalitat de Catalunya, Badalona, Spain
b Departament de Pediatria, d’Obstetrícia i Ginecologia i de Medicina Preventiva i de Salut Publica, Universitat Autònoma de Barcelona, Bellaterra, Spain
c Institut d’Investigació Germans Trias i Pujol (ICTP), Barcelona, Spain
d Agència de Qualitat i Avaluació Sanitàries de Catalunya, Spain
e CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain
f Hospital Clínic-Institut d’Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain

brief report

Introduction: It is unclear if SARS-CoV-2 has affected people living with HIV (PLWH) more. Methods: We compared SARS-CoV-2 testing, test positivity, hospitalisation, intensive care unit (ICU) admission, and mortality between PLWH and the general HIV-negative population of Catalonia, Spain from March 1 to December 15, 2020. Results: SARS-CoV-2 testing was lower among PLWH 3556/13,142 (27.06%) compared to the general HIV-negative population 1,954,902/6,446,672 (30.32%) (p < 0.001) but test positivity was higher among PLWH 21.06% vs. 15.82%, p < 0.001. We observed no significant differences between PLWH and the general population in terms of hospitalisation (13.75% vs. 14.97%, p = 0.174) and ICU admission (0.93% vs. 1.66%, p = 0.059). Among positive cases, we found a lower mortality rate among PLWH compared to the general population (1.74% vs. 3.64%, p = 0.002). Conclusion: PLWH tested less frequently for SARS-CoV-2, had a higher test positivity, similar ICU admission and hospitalisation rates, and lower SARS-CoV-2-associated mortality compared to the general HIV-negative population.

© 2022 Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Published by Elsevier España, S.L.U. All rights reserved.

Evaluación poblacional de la infección por SARS-CoV-2 entre personas que viven con el VIH y la población general de Cataluña (marzo-diciembre de 2020)

Introducción: No está claro si el SARS-CoV-2 ha afectado más a las personas que viven con VIH (PVV). Métodos: Se compararon los test realizados de SARS-CoV-2, la positividad de la prueba, la hospitalización, los ingresos en la unidad de cuidados intensivos (UCI), las tasas de mortalidad entre PVV y la población general de Cataluña desde el 1 de marzo hasta el 15 de diciembre de 2020. Resultados: Los test realizados de SARS-CoV-2 fueron menos entre PVV 3,556/13,142 (27.06%) comparado con la población general de Cataluña 1,954,902/6,446,672 (30.32%) (p < 0.001), pero la positividad de la prueba de SARS-CoV-2 fue mayor entre las PVV (21.06% vs. 15.82%; p < 0.001). No se observaron diferencias estadísticamente significativas entre PVV y la población general en cuanto a hospitalizaciones (13.75% vs. 14.97%; p = 0.174) e ingresos en la UCI (0.93% vs. 1.66%; p = 0.059). Entre los casos positivos, se encontró una menor tasa de mortalidad entre las PVV en comparación con la población general (1.74% vs. 3.64%; p = 0.002).

* Corresponding authors.
E-mail addresses: jmiro@pub.edu (J.M. Miro), jmreyes@iconcologia.net (J. Reyes-Urueña).
1 Equivalent merits as senior authors.

https://doi.org/10.1016/j.eimc.2022.02.006
0213-005X/© 2022 Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Published by Elsevier España, S.L.U. All rights reserved.
Introduction

It is unclear if the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected people living with HIV (PLWH) more. Current data on testing and incidence of SARS-CoV-2 in this population is conflicting.2,3 Intuitively, PLWH should have more opportunities to test for SARS-CoV-2 because this population is considered a high-risk group. However, PLWH had limited access to healthcare and were not routinely tested for SARS-CoV-2 during the current pandemic.4 Testing in Spain was based on the presence of signs and symptoms of coronavirus disease 2019 (COVID-19), chronic comorbidities, older age, and contact tracing.5

Initial studies demonstrated no vivid evidence of poorer disease course among PLWH infected with SARS-CoV-2 compared to HIV-negative individuals.6 As more data become available, large studies have reported poorer outcomes for HIV/SARS-CoV-2 co-infected persons.7 Older age and the presence of underlying chronic conditions like hypertension, diabetes, cardiovascular disease, obesity, and chronic respiratory diseases have been linked with severe COVID-19 outcomes.8 With PLWH in Europe aging and disproportionately affected by comorbidities,8 they could experience poorer prognosis than HIV-negative individuals. The potential enhanced susceptibility of PLWH to SARS-CoV-2 and severe outcomes from the co-infection has become a matter of concern.7

We compared SARS-CoV-2 testing, test positivity, hospitalisation, intensive care unit (ICU) admission, and mortality between PLWH and the general HIV-negative population of Catalonia, Spain.

Methods

We conducted a cross-sectional study leveraging data from the PISCIS cohort of PLWH in Catalonia (Spain). PISCIS is a prospective, multicentre, observational, population-based cohort that monitors hospital utilisation, reception of antiretroviral therapy (ART), and clinical status of approximately 80% of all PLWH aged ≥ 16 years in Catalonia since January 1, 1998. PISCIS data was linked with data from public health care system and disease surveillance registries through the Public Data Analysis for Health Research and Innovation Project of Catalonia (PADRIS)8 to obtain data on SARS-CoV-2 testing and associated outcomes. This work was conducted according to the Declaration of Helsinki as revised in 2013. The PISCIS cohort study has been approved by the Institutional Review Board of Germans Trias i Pujol Hospital, Badalona, Spain (EO-11-108). Patient information obtained from PADRIS was anonymized and deidentified before the analysis.

Aggregated data on the SARS-CoV-2 testing, test positivity, related hospitalisation, ICU admission, and death for the general HIV-negative population within the same study period for individuals aged ≥ 16 years was obtained from COVID-19 epidemiological monitoring registry via the Agency for Health and Quality Assessment of Catalonia (AQuAS). The study period was from March 1, 2020 to December 15, 2020. We used acute SARS-CoV-2 infections confirmed by real-time reverse transcription polymerase chain reaction (rRT-PCR) test or rapid antigen test (RAT). We excluded PLWH from the general population before the analysis.

We calculated SARS-CoV-2 test positivity per the proportion of the population that tested for SARS-CoV-2. Among SARS-CoV-2-positive cases, we determined the rates per 100 persons of hospitalisation, ICU admission, and mortality.

We used the Z-test to compare testing, test positivity, hospitalisation, ICU admission, and mortality between the two populations. We presented our findings using the onion plots concept.

Results

PLWH in our population were predominantly male (81.7%) with a median age of 47.6 years. More than half of PLWH were men who have sex with men (MSM) (52.9%) and 34.8% were of non-Spanish origin. Median CD4 count was 692.5 cells/mm³ and 81.9% had undetectable plasma HIV-RNA (≤50 copies/ml). Regarding treatment, 94.1% of PLWH were on ART with majority receiving tenofovir (57.4%). PLWH had been diagnosed with HIV for a median duration of 12.0 years and 34.2% were without chronic comorbidities (Table 1).

SARS-CoV-2 testing was lower among PLWH 3556/13,142 (27.06%) compared to the general HIV-negative population 1,954,902/6,446,672 (30.32%) (p < 0.001). SARS-CoV-2 test positivity was however higher among PLWH 749/3556 (21.06%, 95% confidence interval [95% CI]: 19.72–22.40) compared to the general population 309,359/1,954,902 (15.82%, 95% CI: 15.76–15.87) (p < 0.001). We observed no significant differences between PLWH and the general population in terms of hospitalisation [103/749 (13.75%, 95% CI: 11.29–16.22) vs 46,318/309,359 (14.97%, 95% CI: 14.85–15.10) (p = 0.174)] and ICU admission [7/749 (0.93%, 95% CI: 0.25–1.62) vs 5140/309,359 (1.66%, 95% CI: 1.62–1.71 p = 0.059)]. Among positive cases, we found a lower mortality rate among PLWH 13/749 (1.74%, 95% CI: 0.80–2.67) compared to the general population 11,272/3,093,599 (3.64%, 95% CI: 3.58–3.71) (p = 0.002) (Fig. 1).

Discussion

In our population-based assessment, SARS-CoV-2 testing was lower among PLWH with higher test positivity compared to the general HIV-negative population. In terms of hospitalisation and ICU admission, no significant differences were observed between the two groups. Mortality was lower among PLWH compared to the general population.

A large study from the USA reported higher testing rates among PLWH compared to HIV-negative individuals.9 The findings of our population-based assessment found otherwise. HIV-positive persons were not prioritised for SARS-CoV-2 testing in Spain.9 During the early days of the pandemic, testing was based on presenting signs and symptoms, comorbidities, age, and contact tracing.3 The fact that PLWH are not prioritized for SARS-CoV-2 testing could mask the real picture of the pandemic in this population. Testing is imperative because it helps to timely identify positive cases including asymptomatic and mildly symptomatic persons and isolate to control spread or initiate early treatment to avoid severe clinical outcomes.

Contrary to other studies that have reported a similar or lower9,10 SARS-CoV-2 incidence among PLWH, our assessment
Table 1
Characteristics of HIV-positive individuals with and without SARS-CoV-2 diagnosis in Catalonia, Spain.

| Characteristic                              | People living with HIV (PLWH) No. (%) | p value |
|---------------------------------------------|---------------------------------------|---------|
|                                             | All (n = 13,142)                      |         |
|                                             | SARS-CoV-2 negative (n = 12,393)      |         |
|                                             | SARS-CoV-2 positive (n = 749)         |         |
| **Sex**                                     |                                       |         |
| Male                                        | 10,739 (81.7)                         | 618 (82.5) | 0.59 |
| Female                                      | 2402 (18.3)                           | 2271 (18.3) | 131 (17.5) |         |
| Missing                                     | 1 (0.01)                              | 1 (0.01) | 0 (0) |         |
| **Age, median (IQR), y**                    | 47.6 (39.6–54.9)                      | 47.8 (39.8–55.0) | 43.5 (37.0–52.7) | <0.001 |
| **Country of origin**                       |                                       |         |
| Spain                                       | 8564 (65.2)                           | 8162 (65.9) | 402 (53.7) | <0.001 |
| Outside Spain                               | 4576 (34.8)                           | 4229 (34.1) | 347 (46.3) |         |
| Unknown                                     | 2 (0.02)                              | 2 (0.02) | 0 (0) |         |
| **HIV transmission route**                  |                                       | <0.001 |
| PWID                                        | 1876 (14.3)                           | 1817 (14.7) | 59 (7.9) |         |
| MSM                                         | 6870 (52.3)                           | 6425 (51.8) | 445 (59.4) |         |
| Male heterosexual                           | 1768 (13.5)                           | 1680 (13.6) | 88 (11.8) |         |
| Female heterosexual                          | 1714 (13.0)                           | 1695 (13.0) | 105 (14.0) |         |
| Other                                       | 787 (6.0)                             | 741 (6.0) | 46 (6.1) |         |
| Missing                                     | 127 (1.0)                             | 121 (1.0) | 6 (0.8) |         |
| **Years since HIV diagnosis, median (IQR)** | 12.0 (7.0–18.7)                      | 12.1 (7.1–18.9) | 10.3 (6.1–15.7) | <0.001 |
| **Recent CD4 count (cells/mm³), median (IQR)** | 692.5 (500.0–917.0) | 692.0 (500.0–917.0) | 695.5 (483.5–912.3) | 0.65 |
| **CD4/CD8 ratio, median (IQR)**             | 0.9 (0.6–1.2)                        | 0.9 (0.6–1.2) | 0.9 (0.6–1.2) | 0.26 |
| **HIV-RNA (recent)**                        |                                       | 0.19    |
| Detectable                                  | 1068 (8.1)                            | 1017 (8.2) | 51 (6.8) |         |
| Undetectable                                | 10,758 (81.8)                        | 10,136 (81.8) | 622 (83.0) |         |
| Missing                                     | 1316 (10.0)                          | 1240 (10.0) | 76 (10.2) |         |
| **Chronic comorbidities**                   |                                       | 0.83    |
| **Number of chronic comorbidities**         |                                       |         |
| 0                                           |                                       |         |
| 1                                           | 4489 (34.2)                           | 4231 (34.1) | 258 (34.5) |         |
| 2                                           | 3434 (26.1)                           | 3247 (26.2) | 187 (25.0) |         |
| 3                                           | 2244 (17.1)                           | 2106 (17.0) | 138 (18.4) |         |
| ≥ 4                                         | 1325 (10.1)                           | 1253 (10.1) | 72 (9.6) |         |
| **Years on ART, median (IQR)**              | 9.4 (5.1–15.0)                        | 9.5 (5.1–15.2) | 7.8 (4.6–12.9) | <0.001 |
| **Backbone ART**                            |                                       | 0.79    |
| TAF                                         | 6606 (50.2)                           | 6215 (50.2) | 391 (52.2) |         |
| TDF                                         | 939 (7.2)                             | 891 (7.2) | 48 (6.4) |         |
| ABC + 3TC                                   | 3820 (29.1)                           | 3594 (29.0) | 226 (30.2) |         |
| Other                                       | 670 (5.1)                             | 630 (5.1) | 40 (5.3) |         |
| Missing                                     | 1107 (8.4)                            | 1063 (8.6) | 44 (5.9) |         |

Abbreviations: SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2; IQR, interquartile range; PWID, people who inject drugs; MSM, men who have sex with men; ART, antiretroviral therapy; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate; ABC, abacavir; 3TC, lamivudine.

* Undetectable HIV/RNA plasma viral load was defined as values ≤50 copies/ml.

Fig. 1. Diagram comparing testing, test positivity, and clinical outcomes of Coronavirus disease 2019 (COVID-19) between PLWH and in the general population of Catalonia (Spain) from March 1, 2020 to December 15, 2020. Abbreviations: PLWH: People living with HIV; ICU, intensive care unit. Rates are provided per 100 persons. Testing is the percentage (%) of the overall population. Hospitalisation, ICU, and mortality are given per 100 persons per number of SARS-CoV-2 infected persons. Z-test was used to compare testing, test positivity, hospitalisation, ICU admission, and mortality between the two populations.
found a higher test positivity in this group. The previously reported lower incidence was attributed to sheltering of PLWH due to perceived vulnerability.\textsuperscript{11,12} Besides sheltering, some studies have suggested that the low SARS-CoV-2 infection rates in this population is due to the potential protection from ART.\textsuperscript{13,14} The therapeutic effects of these anti-HIV agents against SARS-CoV-2 is however inconclusive.\textsuperscript{15} PLWH are disproportionately affected by social determinants including low socioeconomic levels and non-Spanish origin which have been associated with increased SARS-CoV-2 diagnosis in Spain and could partly explain higher test positivity among PLWH.\textsuperscript{13,14}

We found similar rates of COVID-19-associated hospitalisation and ICU admission with lower mortality among PLWH. Earlier studies reported no increased risks of severe outcomes from SARS-CoV-2 infection among HIV-negative individuals.\textsuperscript{5} However, subsequent relatively larger studies showed higher risk of death among PLWH infected with COVID-19.\textsuperscript{5} The variation in the impact of HIV on COVID-19 outcomes could be explained by the differences in severe COVID-19 risk factors present in the study populations. The fact that PLWH are disproportionately affected by other health determinants for worse COVID-19 outcomes makes it uncertain to access the excess risk of HIV on COVID-19.

Our analysis is limited by our inability to adjust for potential confounders including age and chronic comorbidities due to its ecological design as these factors could evidently impact COVID-19 outcomes. A matched analysis adjusted for these factors will be vital to understand the observed differences. Secondly, our analysis involves only individuals engaged in the public health system of Catalonia. Individuals who tested for SARS-CoV-2 in private health facilities, pharmacies, and outside Catalonia would not be captured in the PADRIS records. However, we do not expect this to qualitatively affect the results of our study as the first phases of the pandemic was handled by the public healthcare system with restricted movements to other regions and countries. Finally, we could be underestimating the SARS-CoV-2 diagnosis rates because we only included laboratory confirmed (rRT-PCR or RAT) acute infections in the analysis and moreover, only symptomatic individuals were offered testing at the beginning of the pandemic in Spain.

In summary, PLWH tested less frequently for SARS-CoV-2 infection than the general population, had a higher positivity rate, and similar rates of hospitalisation and ICU admission. Overall, SARS-CoV-2-associated mortality was lower among PLWH. Public health strategies should be employed to increase SARS-CoV-2 testing coverage among PLWH and further studies will be needed to understand the susceptibility of this population to SARS-CoV-2.

Funding

This work was supported by the Fundació “la Caixa” [grant name: COV1HCAT]. The funder had no role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.

Conflicts of interest

J.M.M. reported receiving a personal 80:20 research grant from Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, during 2017–21. For the remaining authors none was declared.

Acknowledgements

We thank the Public Data Analysis for Health Research and Innovation Program of Catalonia (PADRIS) and all healthcare workers from the PISCIS cohort collaborating hospitals for their support.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.ijicim.2022.02.006.

References

1. Ambrosiotti J, Blanco JL, Reyes-uruëña JM, Davies M, Sued O, Marcos MA, et al. Overview of SARS-CoV-2 infection in adults living with HIV. Lancet HIV. 2021;8:294–305.
2. Saglietto A, Moirano G, Anselmino M, De Ferrari GM. Higher testing coverage associated with a lower COVID-19 mortality rate: insights from Italian regions. Disaster Med Public Health Prep. 2020;1:1–3.
3. Chang J, Bruvoxoot K, Chen LH, Akhaban B, Rodriguez J, Hechter RC. COVID-19 testing, characteristics, and outcomes among people living with HIV (PLWH) in an integrated health system. AIDS J Acquir Immune Defic Syndr. 2021.
4. Ballester-Arnal R, Gil-Harri MD. The virus that changed Spain: impact of COVID-19 on people with HIV. AIDS Behav. 2020;24:2253–7, http://dx.doi.org/10.1007/s10461-020-02877-3.
5. Mellor MM, Bast AC, Jones NR, Roberts NW, Oddéz-Mena JM, Reith AJM, et al. Risk of adverse coronavirus disease 2019 outcomes for people living with HIV. AIDS. 2021;35:F1.
6. Pelchen-Matthews A, Ryoom L, Borges ÁH, Edwards S, Duivivier C, Stephán C, et al. Aging and the evolution of comorbidities among HIV-positive individuals in a European cohort. AIDS. 2018;32:2405–16.
7. Brown LB, Spinelli MA, Gandhi M. The interplay between HIV and COVID-19: summary of the data and responses to date. Curr Opin HIV AIDS. 2021;16:63–73.
8. Generalitat de Catalunya. AjTricia de Qualitat i Avaluació Santànes de Catalunya. Programa d’analítica de dades per a la recerca i la innovació en salut a Catalunya – PADRIS [Internet]. Barcelona, Spain; 2017. Available from: https://aquas.gencat.cat/web/content/minisite/aquas/publicacions/2017/Programa_analitica_dades_PADRIS_aquas2017.pdf.
9. Tesoriero JM, Swain C-AE, Pierce JL, Zamboni L, Wu M, Holtgrave DR, et al. COVID-19 outcomes among persons living with or without diagnosed HIV infection in New York State. JAMA Netw Open. 2021;4, http://dx.doi.org/10.1001/jamanetworkopen.2020.37069, e20237069.
10. Huang J, Xie N, Hu X, Yan H, Ding J, Liu P, et al. Epidemiological, virological and serological features of COVID-19 cases in people living with HIV in Wuhan City: a population-based cohort study. Clin Infect Dis. 2020.
11. Spinelli MA, Lynch KL, Yun C, Glibden DV, Peluso MJ, Henrich TJ, et al. SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case–control observational study. Lancet HIV. 2021.
12. Zanella I, Zizzioli D, Castelli F, Quiros-Roldan E, Tenoforov, another inexpensive well-known and widely available old drug repurposed for SARS-CoV-2 infection. Pharmaceuticals. 2021;14:454.
13. Pollán M, Pérez-Gómez B, Pastor-Barrïuso R, Oteo J, Hernànd MA, Pérez-Olmeda M, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet. 2020;535–44.
14. Nomah D, Reyes-Uruëña J, Díaz Y, Moreno S, Aceiton J, Bruguera A, et al. Socio-demographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study. Lancet HIV. 2021;3018:1–10.